Self-assembling multivalent mRNA vaccine against Nipah virus with 75% fatality rate
Background: Bottleneck in Immunological Data and R&D for BSL-4 Containment and Nipah Virus Infection
Zoonotic Nipah virus (NiV) is a WHO-designated priority pathogen with a mortality rate of up to 75%, yet there are no approved vaccines or treatments. Due to the high-risk BSL-4 containment, obtaining real-world wet-lab R&D data is extremely limited. Existing single-antigen analysis guidelines fail to address destructive blind spots in silico, such as cellular dissociation-induced structural collapse noise, thermodynamic instability of multimeric states, and rapid antigen degradation after in vivo administration, leading to failure in maintaining effective inoculation concentrations. In particular, the multidimensional tensor-level mapping of the synergistic interaction between the fusion protein (NiV-F) and attachment protein (NiV-G) complex has exposed significant data bottlenecks in predicting interspecies immune gaps and viral receptor docking blockade.
Discovery: Independent Formulation mRNA-LNP Operation and Single-Cell Scale Neutralizing Antibody Dynamics Tensor Synchronization Demonstration
This study implemented a modality that co-administers mRNA encoding NiV-F and NiV-G, each independently formulated into lipid nanoparticles (LNPs). The docking free energy between antigen and receptor was inversely calculated using differential equation-based rate constants to preemptively calculate LNP uptake efficiency, and batch effects were computationally removed to ensure physicochemical uniformity. A VSV-based NiV pseudovirus surrogate model was constructed to circumvent BSL-4 control, and background noise and false-positive reaction removal algorithms were implemented to measure neutralizing antibody dynamics. This significantly outperforms a simple monovalent vaccine baseline model, elucidating the topological variation of neutralizing antibody dynamics and downstream transcriptome networks within the mouse lymph microenvironment, demonstrating molecular biological integrity.
Establishment of a Model for Receptor Docking Pathway Modulation and Precise Layered Control of Reversible Immune Homeostasis
Based on the omics matrix of the immunoglobulin receptor downstream signaling pathway, a model was established to precisely stratify molecular phenotypes by patient and genetic lineage. Rate-limiting steps determining antigen expression rate and endosomal escape rate were identified, and reversible control of protein translation upregulation and immune response downregulation via pKa control of LNPs was implemented. This designed a backbone that autonomously regulates reversible in vivo immune homeostasis even under severe inflammatory responses. Computational simulations of T cell and memory B cell responses based on the concentration gradient of NiV glycoprotein components formed the core framework for operating a precise control architecture that maintains optimal neutralizing efficacy and prophylactic concentrations.
Prospects: Establishment of a Programmable Infectious Disease Medicine Standard and Implementation of Next-Generation IND Digital Governance
With a projected global NiV market of approximately $3 billion, including Moderna's mRNA-1215 Phase 1 entry, this programmable viromics design platform resets the existing post-hoc symptomatic treatment system into a multidimensional tensor-based computational infrastructure. A computational moat is established by linking genetic gradient correction coefficients in real-time during high-throughput screening (HTS) to optimize antigen combination ratios and eliminate batch-to-batch production variations. This preemptively satisfies global regulatory standards such as the FDA's companion diagnostics (CDx) specifications and drastically shortens the timeline for obtaining clinical trial protocol (IND) and cGMP operational approvals, positioning it as a powerful master asset to drive early commercialization of global biotech pipelines.
INTRODUCTION: Nipah virus (NiV) is a highly pathogenic zoonotic virus associated with a high case fatality rate and human-to-human transmission, and it is listed as a priority pathogen by the World Health Organization (WHO) due to the lack of approved therapeutics or vaccines. NiV is classified as a biosafety level 4 (BSL-4) pathogen, which severely limits experimental studies in the absence of specialized containment facilities. Therefore, the establishment of pseudovirus-based surrogate models is essential for NiV vaccine research. METHODS: In this study, single-antigen mRNA-lipid nanoparticle (mRNA-LNP) vaccines encoding the Nipah virus fusion protein (NiV-F) and attachment protein (NiV-G) were designed and evaluated using a co-administration strategy of independently formulated single-antigen mRNA-LNPs. A Vesicular stomatitis virus (VSV)-based NiV pseudovirus system was established and applied to assess neutralizing antibody responses in a mouse model. RESULTS: The synthesized mRNA-LNP vaccines exhibited high purity and relatively consistent physicochemical properties, indicating uniform formulation characteristics. The VSV-based NiV pseudovirus showed a robust infection signal compared to background controls, and optimization of the purification process effectively reduced non-specific background, enabling reliable evaluation of DISCUSSION: This study provides a foundation for future NiV mRNA-LNP vaccine development and presents a flexible vaccine design approach based on co-administration of independently formulated single-antigen mRNA-LNPs in which mixed administration of single-antigen mRNA-LNPs provides a flexible framework for independently modulating antigen composition and enabling antigen-specific immune responses. These findings provide a basis for future studies exploring diverse antigen combinations in NiV vaccine research.
This study's independent mRNA-LNP co-administration platform goes beyond theoretical exploration of NiV immune mechanisms and directly applies to the actual global vaccine finished product supply chain and next-generation personalized infectious disease therapeutic bio-business lines.
First, by instantly analyzing the receptor binding kinetics of NiV G and F glycoproteins in the clinical setting through in silico computational AI scanning, it eliminates the source of time-lag noise caused by the emergence of variants and antigen structural collapse, thereby protecting the lower limit of effective inoculation concentration for acute encephalitis prevention.
At the same time, by linking to the open-source IEDB database, which aggregates HLA allele and immune cell transcriptome datasets, a companion diagnostic (CDx) panel interface is realized that virtually simulates confounding variables in clinical trial design and real-time inversely calculates effective docking concentrations that induce neutralizing antibody formation.
Furthermore, when multinational corporations conduct large-scale Phase 3 clinical trials for next-generation monoclonal and mRNA vaccines, by linking antigen interference indices and intracellular uptake rates as correction coefficients, batch-to-batch variations in bioavailability are eliminated, and it functions as a backbone infrastructure that maximizes the probability of obtaining clinical trial protocol (IND) and cGMP commercial operation approvals from global regulatory agencies.